[Form 4] Immunovant, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Immunovant, Inc.’s Chief Operating Officer, Gloria Melanie, reported selling a total of 3,115 shares of common stock on May 20, 2026 in open-market transactions at prices including $30.41, $32.15, and $32.95 per share. A footnote explains these sales were executed solely to cover tax withholding obligations arising from the vesting and settlement of 6,872 restricted stock units granted as part of a larger 109,956 RSU award from November 18, 2024. The issuance’s “sell to cover” structure was chosen by the company and described as a mandated, non-discretionary transaction by the executive. The Form 4 data also reflect a reported direct holding of 244,973 shares of Immunovant common stock after the transactions.
Positive
- None.
Negative
- None.
Insights
Small, non-discretionary tax sale tied to RSU vesting, not a directional bet.
COO Gloria Melanie sold 3,115 Immunovant shares via open-market trades on May 20, 2026, with prices including $30.41, $32.15, and $32.95 per share. Form 4 data show continuing direct ownership of 244,973 shares after these transactions.
A key footnote states the sales were required to fund tax withholding on the vesting of 6,872 RSUs from a prior 109,956 RSU grant. The filing characterizes this as a mandated “sell to cover” transaction, meaning the timing and decision to sell were not discretionary.
Because the sale is both relatively small compared with the reported shareholding and undertaken solely for tax obligations, it carries limited informational value about the executive’s view of Immunovant stock. Future company filings may provide additional context on compensation-related equity activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 249 | $30.41 | $8K |
| Sale | Common Stock | 1,168 | $32.15 | $38K |
| Sale | Common Stock | 1,698 | $32.95 | $56K |
Footnotes (1)
- On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.32 - $31.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 - $32.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.55 - $33.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
